Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Prognostische factoren bij prostaatkanker voor patiënten die worden behandeld door waakzaam te wachten (TAPG)

18 november 2026 bijgewerkt door: Queen Mary University of London

The Trans-Atlantic Prostate Group (TAPG) was established to examine the hypothesis that through a detailed retrospective analysis of outcome in a group of men with clinically localised prostate cancer at diagnosis, variables such as biological, pathological and clinical markers, could be identified that might accurately predict the prognosis of clinically localised prostate cancer.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Gedetailleerde beschrijving

In 1999, the TAPG group initiated the "Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting" study, referred to as the TAPG study. It is a retrospective population-based tissue sample study in men diagnosed with localised prostate cancer 1990-2006, inclusively. Initially the cohort comprised men diagnosed with prostate cancer with transurethral resection of the prostate (TURP) and needle biopsies 1990-1996, but was expanded from 2005 to include men diagnosed with prostate cancer 1990 - 2006. Data was collected from six regional cancer registries and eligibility was confirmed via hospital sites, which sent the relevant tissue samples to the TAPG Central Coordinating Office (CCO). Selection of eligible patients for the study completed in 2010. Since this year the TAPG CCO has been collecting cancer registration and mortality updates on the cohort members from regional cancer registries.

Studietype

Observationeel

Inschrijving (Geschat)

3350

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 76 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Mannelijk

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

This is a retrospective, exploratory cohort study and will be carried out in patients registered on UK regional cancer registry databases, as having been diagnosed with prostate cancer between 1990 and 2006, inclusive.

Beschrijving

Inclusion Criteria:

  • Patients must be aged less than 76 years at the time of diagnosis
  • Patients must have had a baseline serum PSA level measured before starting any treatment and within six months of diagnosis
  • Patients must have been diagnosed between 1990 and 2006 with a clinically localized (clinical stage T1-T3, N0 or NX, MO or MX) prostate cancer, in the judgment of the treating physician
  • The initial diagnostic biopsy sample must be available for review. Patients should have (but are not required to have) tissue blocks available for review.
  • There must be no evidence of metastatic disease
  • While data collection will include review of the reports of any imaging studies of the prostate, bones, or soft tissues, these studies are not essential
  • Each patient should have had an adequate medical evaluation to document the status of disease for the first five years after diagnosis. Follow-up should include an annual PSA and digital rectal examination. Records will be reviewed to seek all information about medical evaluation after the time of diagnosis.

Exclusion Criteria:

  • Patients older than 76 years at the time of diagnosis
  • Patients who have not had a baseline serum PSA level measured before starting any treatment
  • Patients who do not have the initial diagnosis biopsy sample for review
  • Patients with evidence of metastatic disease

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: RETROSPECTIVE

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Disease-specific survival
Tijdsspanne: From date of inclusion to date of death from prostate cancer, assessed up to 30 years.

Time from date of inclusion until death from prostate cancer.

From date of inclusion to date of death from prostate cancer, assessed up to 30 years.
Overall survival
Tijdsspanne: From date of inclusion to date of death from any cause, assessed up to 30 years.

Time from date of inclusion until death from any cause.

From date of inclusion to date of death from any cause, assessed up to 30 years.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To evaluate a correlation between serum PSA level and prostate cancer-specific survival.
Tijdsspanne: From date of inclusion to date of death from prostate cancer, assessed up to 30 years.

Correlation of serum PSA level taken within 6 months of date of inclusion compared to death from prostate cancer.

From date of inclusion to date of death from prostate cancer, assessed up to 30 years.
To evaluate a correlation between Gleason score and prostate cancer-specific survival.
Tijdsspanne: From date of inclusion to date of death from prostate cancer, assessed up to 30 years.

Correlation of Gleason Score at date of inclusion compared to death from prostate cancer.

From date of inclusion to date of death from prostate cancer, assessed up to 30 years.
To evaluate an association between clinical stage and prostate cancer-specific survival.
Tijdsspanne: From date of inclusion to date of death from any cause, assessed up to 30 years.

Stratification of clinical stage at date of inclusion compared to death from prostate cancer.

From date of inclusion to date of death from any cause, assessed up to 30 years.
To evaluate ki-67-positive biomarker predictors of prognosis in early prostate cancer.
Tijdsspanne: From date of inclusion to date of death from prostate cancer, assessed up to 30 years.

Correlation of ki-67-positive cells compared to prostate cancer-specific survival.

From date of inclusion to date of death from prostate cancer, assessed up to 30 years.
To evaluate ki-67-positive biomarker predictors of prognosis in early prostate cancer.
Tijdsspanne: From date of inclusion to date of death from any cause, assessed up to 30 years.

Correlation of ki-67-positive cells compared to overall cancer-specific survival.

From date of inclusion to date of death from any cause, assessed up to 30 years.
To evaluate ERG-ETV1 biomarker predictors of prognosis in early prostate cancer.
Tijdsspanne: From date of inclusion to date of death from prostate cancer, assessed up to 30 years.

Correlation of ERG-ETV1 rearrangement status compared to prostate cancer-specific survival.

From date of inclusion to date of death from prostate cancer, assessed up to 30 years.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

12 oktober 1999

Primaire voltooiing (Geschat)

1 januari 2030

Studie voltooiing (Geschat)

1 januari 2030

Studieregistratiedata

Eerst ingediend

14 februari 2019

Eerst ingediend dat voldeed aan de QC-criteria

10 april 2019

Eerst geplaatst (Werkelijk)

11 april 2019

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

18 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren